文献速递肿瘤 PET/CT

68Ga-PSMA-11 PET分期对中高危前列腺癌临床决策的影响

Impact of 68Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-12-04

该回顾性分析纳入116例于2016年4月至2018年5月接受68Ga-PSMA-11 PET/CT或MRI分期的高危或中危前列腺癌患者,在模拟多学科肿瘤委员会中比较基于临床信息+常规影像与基于临床信息+68Ga-PSMA-11 PET的治疗决策。68Ga-PSMA-11 PET在36%患者中提供新信息,27%患者的管理可能因此改变(13%改为不同治疗方式,14%调整治疗细节)。

要点

  • 68Ga-PSMA-11 PET使36%中高危前列腺癌分期患者获得新信息。
  • 27%患者的管理可能因PET信息改变,其中13%改为不同治疗方式。
  • 14%患者治疗细节调整,如放疗野或淋巴结清扫模板修改。

核心结论

  • 68Ga-PSMA-11 PET分期信息有可能改变超过四分之一接受PET分期的高危或中危前列腺癌患者的管理。
  • 基于68Ga-PSMA-11 PET的更个性化治疗决策能否改善患者结局尚需进一步研究。

研究设计与样本

  • 回顾性分析纳入116例于2016年4月至2018年5月接受68Ga-PSMA-11 PET/CT或MRI分期的高危或中危前列腺癌患者。
  • 在模拟多学科肿瘤委员会中,先基于临床信息+常规影像确定假设治疗决策,再与基于临床信息+68Ga-PSMA-11 PET的治疗推荐比较。

主要发现

  • 68Ga-PSMA-11 PET显示原发肿瘤阳性113例(97%)。
  • 检出淋巴结转移28例(24%),骨转移14例(12%)。
  • 与临床分期+常规影像相比,68Ga-PSMA-11 PET在42/116例(36%)中提供新信息。
  • 32/116例(27%)的管理可能改变:15例(13%)改为不同治疗方式,17例(14%)调整治疗细节(如放疗野或淋巴结清扫模板修改)。

临床怎么用

  • 对高危或中危前列腺癌分期,68Ga-PSMA-11 PET可提供常规影像之外的信息,可能影响治疗方式选择或放疗/手术细节。
  • 治疗决策改变对患者结局的获益尚不明确,需进一步研究验证。

局限性

  • 为回顾性分析,样本量116例,来自单中心时间段2016年4月至2018年5月。
  • 管理影响通过模拟多学科肿瘤委员会评估,非真实临床决策。
  • 是否改善患者结局未在本研究中回答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accurate staging is of major importance to determine the optimal treatment modality for patients with prostate cancer. Positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) is a promising technique that outperformed conventional imaging in the detection of nodal and distant metastases in previous studies. However, it is still unclear whether the superior sensitivity and specificity also translate into improved patient management. The aim of this study was to assess the performance of 68Ga-PSMA-11 PET for staging of intermediate and high-risk prostate cancer and its potential impact on disease management. METHODS: In this retrospective analysis, 116 patients who underwent 68Ga-PSMA-11 PET/CT or MRI scans for staging of their intermediate or high-risk prostate cancer between April 2016 and May 2018 were included. The potential impact of 68Ga-PSMA-11 PET staging on patient management was assessed within a simulated multidisciplinary tumour board where hypothetical treatment decisions based on clinical information and conventional imaging alone was determined. This treatment decision was compared with the treatment recommendation based on clinical information and 68Ga-PSMA-11 PET imaging. RESULTS: The primary tumour was positive on 68Ga-PSMA-11 PET in 113 patients (97%). Nodal metastases were detected in 28 patients (24%) and bone metastases in 14 patients (12%). Compared with clinical staging and conventional imaging, 68Ga-PSMA-11 PET resulted in new information in 42 of 116 patients (36%). In 32 of 116 patients (27%), this information would most likely have changed the management into a different therapy modality (15 patients, 13%) or adjusted treatment details (e.g. modification of radiotherapy field or lymph node dissection template; 17 patients, 14%). CONCLUSION: Information from 68Ga-PSMA-11 PET staging has the potential to change the management in more than a fourth of the patients who underwent PET staging for their intermediate to high-risk prostate cancer. Whether these more personalized 68Ga-PSMA-11 PET-based treatment decisions will improve patient outcome needs further investigation.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ferraro DA, Garcia Schüler HI, Muehlematter UJ, et al. Impact of 68Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer. Eur J Nucl Med Mol Imaging. 2019. PMID: 31802175. doi:10.1007/s00259-019-04568-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。